Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase 2 trial of two chemotherapy regimens plus or minus bevacizumab in patients with well differentiated pancreatic neuroendocrine tumors
2023-505286-84-00Phase 2Authorised
- Sponsor
- Gustave Roussy
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab in islet cell tumor, sponsored by Gustave Roussy. Planned start Mar 2024; status: authorised.
02
Drugs
bevacizumab
03
Conditions
islet cell tumor
Beyond the preview
Go deeper on 2023-505286-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505286-84-00.